Beck Mack & Oliver LLC Has $115.75 Million Stake in Abbott Laboratories $ABT

Key Points

• Beck Mack & Oliver raised its stake in Abbott Laboratories by 2.1% to 864,174 shares worth about $115.75 million, making ABT the firm's 19th largest holding and 2.1% of its portfolio.
• Abbott reported quarterly EPS of $1.50 (in line with estimates) but missed revenue at $11.46 billion; the company issued Q1 2026 guidance of 1.120–1.180 EPS and FY2026 guidance of 5.550–5.800 EPS.
• Abbott declared a quarterly dividend of $0.63 per share (annualized $2.52, ~2.3% yield) while analysts have trimmed price targets, leaving an average target of $136.16 and a consensus rating of "Moderate Buy."

Beck Mack & Oliver LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 2.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 864,174 shares of the healthcare product maker's stock after buying an additional 17,771 shares during the period. Abbott Laboratories accounts for 2.1% of Beck Mack & Oliver LLC's portfolio, making the stock its 19th largest holding. Beck Mack & Oliver LLC's holdings in Abbott Laboratories were worth $115,748,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Carr Financial Group Corp increased its stake in shares of Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker's stock worth $520,000 after purchasing an additional 76 shares during the last quarter. Tortoise Investment Management LLC lifted its stake in shares of Abbott Laboratories by 10.7% in the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker's stock valued at $108,000 after purchasing an additional 77 shares during the last quarter. Gemmer Asset Management LLC boosted its holdings in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker's stock worth $368,000 after purchasing an additional 78 shares in the last quarter. Global Financial Private Client LLC increased its position in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker's stock worth $331,000 after buying an additional 79 shares during the last quarter. Finally, Citizens & Northern Corp raised its holdings in Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker's stock valued at $2,930,000 after buying an additional 79 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 0.1%

Shares of ABT opened at $107.99 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a 50-day simple moving average of $114.58 and a 200-day simple moving average of $123.86. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The firm has a market capitalization of $187.66 billion, a P/E ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the company posted $1.34 earnings per share. The company's quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ABT shares. Piper Sandler decreased their price target on Abbott Laboratories from $150.00 to $135.00 and set an "overweight" rating for the company in a research note on Friday, January 23rd. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a report on Friday, January 23rd. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating on the stock in a report on Friday, January 23rd. The Goldman Sachs Group dropped their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, January 23rd. Finally, BTIG Research decreased their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a "buy" rating for the company in a report on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $136.16.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.